Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPF vs PF Induction or CRT in LAHNC
NCT00261703Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2002
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of docetaxel in head and neck cancer (HNC) (3 arms), sponsored by Sanofi. Primary endpoints: Clinical Objective Response Rate at 16 weeks and Progression-Free Survival at 2 years. Started Dec 2002; status: completed.
02
Drugs
docetaxel
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00261703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261703.